Optimal Dose https://validator.w3.org/feed/docs/rss2.html Weekly News 19 September to 25 September 2026 Weekly News 19 September to 25 September 2026 Iza-bren granted BTD in China for the treatment of mTNBC Telix and ITM join forces to create a radiopharmaceutical powerhouse BoomRay enters exclusive global license agreement with Novartis for a novel radioligand therapy asset SOTIO advances SOT106 with dual FDA designations for Sarcoma PADCEV + Keytruda receives positive CHMP opinion for resectable MIBC Enhertu receives CHMP recommendation for adjuvant treatment of HER2-positive early Breast cancer Optimal Dose – CAR-T Digest (August 2020) Weekly News 17 October to 23 October 2026 Weekly News 17 October to 23 October 2026 Enhertu approved in China for previously treated patients with HER2+ metastatic Solid tumors Hansoh Pharma announces strategic collaboration and license agreement with Roche to advance novel ADC portfolio BioNTech and Gilead partner to evaluate Pumitamig plus Trodelvy in 1L TNBC Medicovestor announces FDA FTD for MC001, a FIC ADC for Pancreatic cancer Samsung Bioepis receives FDA FTD for SBE303 for the treatment of Urothelial cancer European Commission expands PADCEV + Keytruda approval to resectable MIBC, regardless of cisplatin eligibility Sino Biopharmaceutical announces NDA acceptance for TQB2102 in HER2-low Breast cancer in China ELAHERE approved in Japan for patients with FRα-positive, platinum-resistant recurrent Ovarian cancer SYS6010 received NMPA BTD in China for actionable genomic alteration-negative non-squamous NSCLC Weekly News 12 September to 18 September 2026 Weekly News 12 September to 18 September 2026 Escugen and Sovran expand collaboration to co-develop a novel bispecific ADC Hengrui’s HER3 ADC, SHR-A2009 for injection, included in China’s Breakthrough Therapy list for NSCLC Weekly News 10 October to 16 October 2026 Weekly News 10 October to 16 October 2026 MacroGenics dosed the first patient in the phase 1 trial of MGC030 for advanced Solid tumors Adlai Nortye partnered with Lilly and Merck KGaA to evaluate AN4035 in combination with cetuximab Alentis and PinotBio partnered to develop next-generation CLDN1-targeting ADCs DR30206 fusion protein received China IND approval for combination therapy in HNSCC SYS6062 ADC received clinical trial approval in China Iza-Bren combination with radiotherapy received NMPA clinical trial approval for HNSCC Weekly News 03 October to 09 October 2026 Weekly News 03 October to 09 October 2026 Enhertu approved in China for HER2-positive early Breast cancer with residual disease AstraZeneca and Daiichi Sankyo collaborate with Summit Therapeutics to evaluate Datroway plus Ivonescimab across multiple tumor types [²¹²Pb]PSV359 receives FDA Fast Track Designation for FAP-positive solitary fibrous tumors AbbVie’s Temab-A receives FDA Breakthrough Therapy Designations for CRC and NSCLC Crescent Biopharma receives FDA IND clearance for CR-002 in Solid tumors Datroway approved in China for metastatic TNBC ineligible for PD-1/PD-L1 inhibitors Ifinatamab deruxtecan BLA for previously treated extensive-stage SCLC was voluntarily withdrawn in the U.S. BL-M05D1 received BTD in China for previously treated advanced Gastric/GEJ cancer Weekly News 26 September to 02 October 2026 Weekly News 26 September to 02 October 2026 Perioperative Imfinzi plus Enfortumab vedotin received U.S. FDA Priority Review for MIBC AstraZeneca announced an equity investment and clinical collaboration with Summit Therapeutics to advance ADC combinations in cancer Nurix Therapeutics announced a $7 million milestone achievement under its strategic collaboration with Pfizer Dong-A ST and Galux entered a research collaboration to develop AI-designed antibodies for ADC therapeutics Monthly Digest – October 2026 Monthly Digest – October 2026